Owens & Minor ( (OMI) ) has released its Q4 earnings. Here is a breakdown of the information Owens & Minor presented to its investors.
Owens & Minor, Inc. is a Fortune 500 global healthcare solutions company that provides essential products and services supporting care from hospitals to homes, leveraging brands like Apria, Byram, and HALYARD.
In its latest earnings report, Owens & Minor announced a significant reduction in total debt by $244 million in 2024, culminating in a two-year total debt reduction of $647 million. The company is also in active discussions regarding the potential sale of its Products & Healthcare Services segment and has authorized a share repurchase program of up to $100 million.
Key financial highlights include a slight increase in revenue to $10.7 billion in 2024 from $10.3 billion in 2023. However, the company reported a GAAP net loss of $363 million for the year, attributed to a goodwill impairment charge of $305 million. Adjusted EBITDA remained relatively stable at $523 million. The company is focusing on its higher growth and margin Patient Direct segment, which showed strong performance.
Looking ahead, Owens & Minor projects revenue for 2025 to range between $10.85 billion and $11.15 billion, with expectations of double-digit adjusted EBITDA and EPS growth. The management remains optimistic about the future, driven by strategic initiatives and market trends supporting home-based care.